---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-016029"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T11:27:36.452564+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# DiaMedica appoints former Medtronic CMO Richard Kuntz to Board of Directors

## Summary
- Dr. Kuntz appointed effective May 30, 2023; he recently retired as Medtronic's Chief Medical and Scientific Officer.
- He received an option to purchase 32,320 voting common shares at fair market value, vesting quarterly over 3 years.
- Kuntz will receive standard non-employee director compensation and a standard indemnification agreement.
- His expertise in stroke and clinical trial design aligns with DiaMedica's ReMEDy2 acute ischemic stroke trial.
- Kuntz founded the Harvard Clinical Research Institute and served on boards of ZimVie and Identiv.

## SEC filing metadata
- accession: 0001437749-23-016029
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774923016029/0001437749-23-016029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774923016029/dmtp20230529_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-016029
- JSON: https://secwatch.observer/filing/0001437749-23-016029.json
- Plain text: https://secwatch.observer/filing/0001437749-23-016029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.